Stoke Therapeutics, Inc. (NASDAQ:STOK) reported its fourth-quarter financial results and announced Phase 1/2a end of study data after the bell on Monday. Here’s a look at the highlights. The Details: The company reported quarterly losses of 60 cents per share which beat the analyst consensus estimate of 63 cents per share by 4.76%. Quarterly sales came in at $2.8 million which missed the analyst consensus estimate of $3.25 million by 13.82% and is a 14.32% decrease over sales of $3.27 million from the same period last year. Stoke Therapeutics announced new data from two open-label Phase 1/2a s…